神州细胞：安佳因2025年销售下降的主要影响因素

Group 1 - The core viewpoint of the article highlights a significant decline in sales of the product Anjiaan® in 2025, attributed to several factors including medical insurance cost control leading to reduced patient usage [2] - The company has implemented a substantial price reduction for Anjiaan® starting from the third quarter of 2025 in response to the National Medical Insurance Administration's call, aiming to benefit patients and improve their survival conditions [2] - The revised "Guidelines for the Treatment of Hemophilia in China (2025 Edition)" has redefined treatment approaches for coagulation disorders, emphasizing the importance of preventive treatment and calling for better protection for adult patients similar to that of children [2]